Fennec Pharmaceuticals Inc.
TSX:FRX.TOBiotechnology
-$0.22 today
- Market cap
- $676.80M
- Beta
- 1.08
- P/E (TTM)
- -36.5
- EPS (TTM)
- -$0.24
Volume 0.00M
Average 0.00M
FRX.TO Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Fennec Pharmaceuticals Inc.TSX: FRX.TO
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin holds steady near 96.2%
Gross margin was 96.2% in Q1 FY2026, up 0.5 pp from a year earlier. On a trailing-twelve-month basis it was 92.2%, up 1.9 pp year over year. Over 3 fiscal years it narrowed by 2.8 pp.
Context
- Gross margin widened in 0 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 91.6%
- Year-over-year change
- -1.7pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 91.6% | -1.7pp |
| FY2024 | 2024-12-31 | 93.3% | -0.8pp |
| FY2023 | 2023-12-31 | 94.1% | -0.3pp |
| FY2022 | 2022-12-31 | 94.4% | — |
| FY2021 | 2021-12-31 | — | — |
Gross Margin vs competitors
How FRX.TO compares with its peers on the latest reported figures
- FRX.TO's LTM Mar 2026 gross margin of 92.2% is the highest of the 6 companies compared; the peer median is 44.5%.
- Its year-over-year change of +1.9 pp is the 2nd highest of 6, against a peer median of -5.9 pp.
- Over three fiscal years its change of -2.8 pp compares with a peer median of +13.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 92.2% | +1.9 pp | -2.8 pp | |
PRN.TOProfound Medical Corp. | LTM Mar 2026 | 71.0% | +4.1 pp | +25.6 pp |
| LTM Mar 2026 | 50.9% | -0.7 pp | +0.4 pp | |
| LTM Mar 2026 | 44.5% | -21.3 pp | -28.1 pp | |
| LTM Mar 2026 | 23.6% | -5.9 pp | +54.0 pp | |
| LTM Mar 2026 | -3.1% | -35.8 pp | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding FRX.TO) | 44.5% | -5.9 pp | +13.0 pp | |
Competitors are the stored peer set for FRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 1.54M | 21.25M | 47.54M | 44.64M |
| Cost of Revenue | 0 | 86K | 1.26M | 3.18M | 3.76M |
| Gross Profit | 0 | 1.45M | 19.99M | 44.35M | 40.88M |
| Gross Margin | — | 94.4% | 94.1% | 93.3% | 91.6% |
| Research & Development | 4.98M | 3.53M | 56K | 307K | 254.38K |
| Selling, General & Admin | 12.24M | 20.51M | 32.71M | 41.48M | 46.91M |
| Operating Expenses | 17.22M | 24.04M | 32.76M | 41.79M | 47.22M |
| Depreciation & Amortization | 17.22M | 149K | 287K | 800K | 103K |
| EBITDA | (17.19M) | (22.74M) | (12.65M) | 4.8M | (7.45M) |
| EBITDA Margin | — | -1481.2% | -59.5% | 10.1% | -16.7% |
| Operating Income | (17.22M) | (22.59M) | (12.77M) | 2.57M | (6.35M) |
| Operating Margin | — | -1471.6% | -60.1% | 5.4% | -14.2% |
| Interest Income | 54K | 195K | 441K | 1.68M | 800.78K |
| Interest Expense | 126K | 978K | 3.39M | 4.07M | 2.18M |
| Other Income / Expenses | (123K) | (1.13M) | (3.27M) | (2.64M) | (3.29M) |
| Income Before Tax | (17.35M) | (23.71M) | (16.05M) | (71K) | (9.64M) |
| Pre-Tax Margin | — | -1544.9% | -75.5% | -0.1% | -21.6% |
| Income Tax Expense | 110K | 147K | 0 | 365K | 106K |
| Net Income | (17.46M) | (23.86M) | (16.05M) | (436K) | (9.74M) |
| Net Margin | — | -1554.5% | -75.5% | -0.9% | -21.8% |
| EPS (Basic) | (0.67) | (0.91) | (0.60) | (0.02) | (0.34) |
| EPS (Diluted) | (0.67) | (0.91) | (0.60) | (0.02) | (0.34) |
| Weighted Avg Shares | 25.89M | 26.28M | 26.57M | 21.8M | 28.58M |
| Weighted Avg Shares (Diluted) | 26.01M | 26.28M | 26.57M | 27.3M | 28.58M |
Fennec Pharmaceuticals Inc.
TSX:FRX.TO
Intrinsic Alpha fair value
Locked
Current Price
$19.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.